Usha Sharma – Mumbai
Chandigarh-based leading active pharmaceutical ingredient (API) manufacturer Ind-Swift Laboratories is looking for a partner for accelerating company’s growth. The partnership could take the form of a strategic equity investment as well.
NR Munjal, Vice-Chairman cum Managing Director, Ind Swift Laboratories said, “We are having a good base in R&D, formulations and marketing field force. We have more than 100 scientists at one of the largest API manufacturing sites in India which have been approved by UK-MHRA, US-FDA, Australia’s TGA, and many more regulatory agencies which are required for exports.”
Munjal elaborated, “ We are looking for a partner with synergies with our business with whom we can take the existing business to the next level.”
Presently, the company’s domestic formulation business has grown rapidly. It has over 1500 medical representatives with nearly 150 branded products. The company has developed fully integrated distribution centres. At present it has five depots and 30 CNS centres who basically manages company’s entire supply chain distribution system.
The company has multi-locational manufacturing sites which produce active pharmaceutical ingredients (API). The company’s WHO-GMP approved manufacturing facility at Punjab with 17 manufacturing blocks comprises a pilot plant, dedicated blocks and multi-purpose blocks designed to comply with stringent US FDA and other regulatory standards. It has fully approved sites from different regulator bodies like UK-MHRA, US-FDA, Brazil Anvisa, TGA- Australia, Middle East GCC and many more.
Ind-Swift is exporting to almost 50 countries worldwide medicines worth over Rs 200 crore which are manufactured from its Dera Bassi plant near Chandigarh.
While responding on the actual volume of fund infusion/ equity sale involved, Munjal replied, “Currently, we have not decided on the amount. Basically we are focussing on the synergy model which will help our company to grow in a much faster way.”
- Advertisement -
